Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMMX Immix Biopharma	$2.19 -3.9%	$2.51	$1.26 ▼ $3.20	$63.15M	0.28	254,769 shs	175,020 shs
OSTX OS Therapies	$2.48 +3.3%	$1.83	$1.12 ▼ $7.00	$79.09M	N/A	737,634 shs	1.08 million shs
OVID Ovid Therapeutics	$1.03 +7.6%	$0.52	$0.24 ▼ $1.47	$73.24M	0.2	1.53 million shs	1.20 million shs
PULM Pulmatrix	$4.89 +9.4%	$6.07	$1.78 ▼ $10.40	N/A	1.45	11,293 shs	14,341 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMMX Immix Biopharma	0.00%	-3.52%	-21.51%	+10.05%	-3.95%
OSTX OS Therapies	0.00%	+20.39%	+43.35%	+47.62%	-38.00%
OVID Ovid Therapeutics	0.00%	+6.19%	+48.63%	+261.02%	-13.45%
PULM Pulmatrix	0.00%	+3.82%	-12.83%	-28.19%	+135.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMMX Immix Biopharma	3.2417 of 5 stars	3.5	5.0	0.0	0.6	3.3	0.6
OSTX OS Therapies	2.1688 of 5 stars	3.6	0.0	0.0	2.2	0.8	0.6
OVID Ovid Therapeutics	4.2015 of 5 stars	3.6	3.0	4.6	2.0	2.5	0.0
PULM Pulmatrix	0.4152 of 5 stars	0.0	5.0	0.0	1.1	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMMX Immix Biopharma	3.00	Buy	$7.00	219.63% Upside
OSTX OS Therapies	3.25	Buy	$18.00	625.81% Upside
OVID Ovid Therapeutics	3.17	Buy	$3.10	200.97% Upside
PULM Pulmatrix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PULM, OSTX, IMMX, and OVID Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/8/2025	OVID Ovid Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
8/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.16 per share	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	$570K	128.50	N/A	N/A	$0.78 per share	1.32
PULM Pulmatrix	$7.81M	N/A	N/A	N/A	$2.45 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMMX Immix Biopharma	-$21.61M	-$0.77	N/A	N/A	N/A	N/A	-205.35%	-110.63%	11/11/2025 (Estimated)
OSTX OS Therapies	-$7.79M	-$0.79	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
OVID Ovid Therapeutics	-$26.43M	-$0.53	N/A	N/A	N/A	-574.44%	-58.87%	-43.18%	11/11/2025 (Estimated)
PULM Pulmatrix	-$6.94M	-$2.17	N/A	∞	N/A	-122.46%	-97.25%	-88.96%	11/6/2025 (Estimated)

Latest PULM, OSTX, IMMX, and OVID Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	OVID Ovid Therapeutics	-$0.16	-$0.06	+$0.10	-$0.06	$0.09 million	$6.27 million
8/8/2025	Q1 2025	IMMX Immix Biopharma	-$0.21	-$0.22	-$0.01	-$0.22	N/A	N/A
8/6/2025	Q2 2025	PULM Pulmatrix	N/A	-$0.42	N/A	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
PULM Pulmatrix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMMX Immix Biopharma	N/A	1.23	1.23
OSTX OS Therapies	N/A	0.76	0.76
OVID Ovid Therapeutics	0.23	4.72	4.72
PULM Pulmatrix	N/A	11.21	11.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMMX Immix Biopharma	11.26%
OSTX OS Therapies	N/A
OVID Ovid Therapeutics	72.24%
PULM Pulmatrix	11.84%

Insider Ownership

Company	Insider Ownership
IMMX Immix Biopharma	55.40%
OSTX OS Therapies	13.80%
OVID Ovid Therapeutics	13.10%
PULM Pulmatrix	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMMX Immix Biopharma	9	28.83 million	12.86 million	Optionable
OSTX OS Therapies	N/A	31.89 million	N/A	N/A
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable
PULM Pulmatrix	20	N/A	N/A	Not Optionable

PULM, OSTX, IMMX, and OVID Headlines

Recent News About These Companies

Pulmatrix (PULM) Q2 Revenue Falls 100%

August 6, 2025 | fool.com

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

August 6, 2025 | prnewswire.com

Pulmatrix Inc.

June 2, 2025 | barrons.com

Pulmatrix set for merger with Cullgen, seeks asset divestment

May 17, 2025 | uk.investing.com

Pulmatrix Inc.: Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 15, 2025 | finanznachrichten.de

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 15, 2025 | prnewswire.com

Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide

April 3, 2025 | theglobeandmail.com

Pulmatrix Reports 2024 Financials and Merger Plans

March 24, 2025 | tipranks.com

Pulmatrix Inc.: Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

March 21, 2025 | finanznachrichten.de

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

March 21, 2025 | prnewswire.com

Pulmatrix revises bylaws, changes voting standards

February 14, 2025 | msn.com

Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain

January 23, 2025 | finance.yahoo.com

How to Take Advantage of moves in (PULM)

January 11, 2025 | news.stocktradersdaily.comN

When the Price of (PULM) Talks, People Listen

December 11, 2024 | news.stocktradersdaily.comN

Pulmatrix Inc (PULM) Stock: Surpassing Expectations in the Market

November 19, 2024 | bovnews.comB

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

November 15, 2024 | accesswire.comA

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULM

November 15, 2024 | bakersfield.comB

PULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. Merger

November 14, 2024 | accesswire.comA

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Pulmatrix, Inc. – PULM

November 14, 2024 | globenewswire.com

Pulmatrix Inc.: Pulmatrix and Cullgen Announce Proposed Merger

November 14, 2024 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

PULM, OSTX, IMMX, and OVID Company Descriptions

Immix Biopharma NASDAQ:IMMX

$2.19 -0.09 (-3.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.18 0.00 (-0.23%)

As of 08/22/2025 07:39 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

OS Therapies NYSE:OSTX

$2.48 +0.08 (+3.33%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.43 -0.05 (-2.18%)

As of 08/22/2025 07:31 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Ovid Therapeutics NASDAQ:OVID

$1.03 +0.07 (+7.63%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.03 0.00 (-0.10%)

As of 08/22/2025 07:47 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Pulmatrix NASDAQ:PULM

$4.77 +0.30 (+6.62%)

As of 08/22/2025 04:00 PM Eastern

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time